Targets › PDE4
4 programs from 4 companies in 10 trials: 7 Phase 3, 2 Phase 2, 1 Phase 1; Immunology, Respiratory; next expected readout Nov 2026.
Open in Phaseline: the race on PDE4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | TQC3721 Suspension for Inhalation Phosphodiesterase 3/4 (PDE3/4) inhibitor | PDE3, PDE4 | Phase 3 | Chronic Obstructive Pulmonary Disease | Feb 2027 |
| Boehringer Ingelheim | Nerandomilast formulation 1 Phosphodiesterase 4 (PDE4) inhibitor | PDE4 | Phase 3 | Interstitial Lung Diseases; Idiopathic Pulmonary Fibrosis; Fibrosing Interstitial Lung Disease; Familial Pulmonary Fibrosis … | Apr 2027 |
| Scleroderma Research Foundation, Inc. | BI 1015550 (Nerandomilast) Phosphodiesterase-4 (PDE4) inhibitor | PDE4 | Phase 2 | Interstitial Lung Disease Due to Systemic Disease | Nov 2026 |
| Palisade Bio | PALI-2108 phosphodiesterase-4 (PDE4) inhibitor | PDE4 | Phase 2 | Ulcerative Colitis (UC); Fibrostenotic Crohn's Disease | Oct 2027 |
Interstitial Lung Diseases (2) Idiopathic Pulmonary Fibrosis (1) Fibrosing Interstitial Lung Disease (1) Familial Pulmonary Fibrosis (1) Systemic Sclerosis (1) Chronic Obstructive Pulmonary Disease (1) Ulcerative Colitis (UC) (1) Fibrostenotic Crohn's Disease (1) Interstitial Lung Disease Due to Systemic Disease (1)
small molecule (3), mixed (1)
Boehringer Ingelheim (1) Chia Tai Tianqing Pharmaceutical Group (1) Palisade Bio (1) Scleroderma Research Foundation, Inc. (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.